A detailed history of E Fund Management Co., Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 116,745 shares of LEGN stock, worth $3.83 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
116,745
Previous 58,426 99.82%
Holding current value
$3.83 Million
Previous $2.59 Million 119.87%
% of portfolio
0.3%
Previous 0.14%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$43.55 - $59.88 $2.54 Million - $3.49 Million
58,319 Added 99.82%
116,745 $5.69 Million
Q2 2024

Aug 12, 2024

BUY
$39.5 - $57.22 $54,273 - $78,620
1,374 Added 2.41%
58,426 $2.59 Million
Q1 2024

May 13, 2024

SELL
$55.06 - $69.99 $376,885 - $479,081
-6,845 Reduced 10.71%
57,052 $3.2 Million
Q4 2023

Feb 06, 2024

BUY
$57.25 - $69.74 $637,650 - $776,764
11,138 Added 21.11%
63,897 $3.84 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $68,212 - $82,620
1,080 Added 2.09%
52,759 $3.54 Million
Q2 2023

Aug 11, 2023

SELL
$46.28 - $75.01 $149,669 - $242,582
-3,234 Reduced 5.89%
51,679 $3.57 Million
Q1 2023

May 11, 2023

SELL
$43.42 - $57.37 $17.2 Million - $22.7 Million
-395,663 Reduced 87.81%
54,913 $2.65 Million
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $16.2 Million - $23.2 Million
417,567 Added 1265.01%
450,576 $6.29 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $59,704 - $89,361
1,565 Added 4.98%
33,009 $1.35 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $1.05 Million - $1.73 Million
31,444 New
31,444 $1.73 Million
Q1 2022

May 12, 2022

SELL
$31.02 - $48.18 $276,915 - $430,102
-8,927 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$41.14 - $56.98 $367,256 - $508,660
8,927 New
8,927 $416,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.